Nuzenio

Adneuris Therapeutics

Adneuris Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 4 publisher sources 100/100 entity strength

Latest news

Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea - BioPharma APACBioPharma APAC · Sat, 08 Aug 2026 16:11:34 GMTAdneuris licenses cebranopadol to Maruishi in second ex-US deal within four weeks - AllSciAllSci · Wed, 05 Aug 2026 14:51:55 GMTAdneuris Therapeutics - The Pharma LetterThe Pharma Letter · Wed, 05 Aug 2026 13:34:18 GMTAdneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 12:30:00 GMT

Timeline

Sat, 08 Aug 2026 16:11:34 GMTAdneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea - BioPharma APAC
Wed, 05 Aug 2026 14:51:55 GMTAdneuris licenses cebranopadol to Maruishi in second ex-US deal within four weeks - AllSci
Wed, 05 Aug 2026 13:34:18 GMTAdneuris Therapeutics - The Pharma Letter
Wed, 05 Aug 2026 12:30:00 GMTAdneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea - Yahoo Finance

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Adneuris Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

4 distinct publisher/source names are currently connected to this entity page.